Cargando…

Risk factors and molecular epidemiology of community-onset, multidrug resistance extended-spectrum β-lactamase-producing Escherichia coli infections

BACKGROUND/AIMS: Although multidrug resistance (MDR) among extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC) poses significant therapeutic challenges, little is known regarding the risk factors and epidemiology of community-onset MDR-ESBL-EC infections. We performed this study to in...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, So Yeon, Kang, Cheol-In, Wi, Yu Mi, Chung, Doo Ryeon, Peck, Kyong Ran, Lee, Nam-Yong, Song, Jae-Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5214718/
https://www.ncbi.nlm.nih.gov/pubmed/27093979
http://dx.doi.org/10.3904/kjim.2015.113
_version_ 1782491655511736320
author Park, So Yeon
Kang, Cheol-In
Wi, Yu Mi
Chung, Doo Ryeon
Peck, Kyong Ran
Lee, Nam-Yong
Song, Jae-Hoon
author_facet Park, So Yeon
Kang, Cheol-In
Wi, Yu Mi
Chung, Doo Ryeon
Peck, Kyong Ran
Lee, Nam-Yong
Song, Jae-Hoon
author_sort Park, So Yeon
collection PubMed
description BACKGROUND/AIMS: Although multidrug resistance (MDR) among extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC) poses significant therapeutic challenges, little is known regarding the risk factors and epidemiology of community-onset MDR-ESBL-EC infections. We performed this study to investigate risk factors and the molecular epidemiology of community-onset MDR-ESBL-EC infections. METHODS: We conducted a case-control-control study of community-onset infections. MDR-ESBL-EC was defined as ESBL-EC that demonstrated in vitro resistance to trimethoprim-sulfamethoxazole, fluoroquinolones (FQs), and gentamicin. Patients with MDR-ESBL-EC infections were designated as case patients. A control group I (CG I) patient was defined as a person whose clinical sample yielded ESBL-EC that did not meet the criteria for MDR. A control group II (CG II) patient was defined as a patient with a non-ESBL-EC infection. RESULTS: Of 108 patients with ESBL-EC infections, 30 cases (27.8%) were due to MDR-ESBL-EC. Compared with CG I, prior use of FQs (odds ratio [OR], 3.16; 95% confidence interval [CI], 1.11 to 8.98) and immunosuppressant use (OR, 10.47; 95% CI, 1.07 to 102.57) were significantly associated with MDR-ESBL-EC. Compared with CG II, prior use of FQs (OR, 15.53; 95% CI, 2.86 to 84.27) and healthcare-associated infection (OR, 5.98; 95% CI, 2.26 to 15.86) were significantly associated with MDR-ESBL-EC. CTX-M-15 was the most common in MDR-ESBL-EC infections (59.1% [13/22]), while CTX-M-14 was the most common in non-MDR-ESBL-EC infections (41.6% [32/77]). CTX-M-15 was significantly associated with MDR-ESBL-EC (59.1% vs. 32.5%, p = 0.028). Pulsed-field gel electrophoresis showed clonal diversity of MDR-ESBL-EC isolates. CONCLUSIONS: The emergence of strains of MDR-ESBL-EC in the community poses an important new public health threat. More information on the emergence and transmission of these strains will be necessary in order to prevent their spread.
format Online
Article
Text
id pubmed-5214718
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher The Korean Association of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-52147182017-01-11 Risk factors and molecular epidemiology of community-onset, multidrug resistance extended-spectrum β-lactamase-producing Escherichia coli infections Park, So Yeon Kang, Cheol-In Wi, Yu Mi Chung, Doo Ryeon Peck, Kyong Ran Lee, Nam-Yong Song, Jae-Hoon Korean J Intern Med Original Article BACKGROUND/AIMS: Although multidrug resistance (MDR) among extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC) poses significant therapeutic challenges, little is known regarding the risk factors and epidemiology of community-onset MDR-ESBL-EC infections. We performed this study to investigate risk factors and the molecular epidemiology of community-onset MDR-ESBL-EC infections. METHODS: We conducted a case-control-control study of community-onset infections. MDR-ESBL-EC was defined as ESBL-EC that demonstrated in vitro resistance to trimethoprim-sulfamethoxazole, fluoroquinolones (FQs), and gentamicin. Patients with MDR-ESBL-EC infections were designated as case patients. A control group I (CG I) patient was defined as a person whose clinical sample yielded ESBL-EC that did not meet the criteria for MDR. A control group II (CG II) patient was defined as a patient with a non-ESBL-EC infection. RESULTS: Of 108 patients with ESBL-EC infections, 30 cases (27.8%) were due to MDR-ESBL-EC. Compared with CG I, prior use of FQs (odds ratio [OR], 3.16; 95% confidence interval [CI], 1.11 to 8.98) and immunosuppressant use (OR, 10.47; 95% CI, 1.07 to 102.57) were significantly associated with MDR-ESBL-EC. Compared with CG II, prior use of FQs (OR, 15.53; 95% CI, 2.86 to 84.27) and healthcare-associated infection (OR, 5.98; 95% CI, 2.26 to 15.86) were significantly associated with MDR-ESBL-EC. CTX-M-15 was the most common in MDR-ESBL-EC infections (59.1% [13/22]), while CTX-M-14 was the most common in non-MDR-ESBL-EC infections (41.6% [32/77]). CTX-M-15 was significantly associated with MDR-ESBL-EC (59.1% vs. 32.5%, p = 0.028). Pulsed-field gel electrophoresis showed clonal diversity of MDR-ESBL-EC isolates. CONCLUSIONS: The emergence of strains of MDR-ESBL-EC in the community poses an important new public health threat. More information on the emergence and transmission of these strains will be necessary in order to prevent their spread. The Korean Association of Internal Medicine 2017-01 2016-04-20 /pmc/articles/PMC5214718/ /pubmed/27093979 http://dx.doi.org/10.3904/kjim.2015.113 Text en Copyright © 2017 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Park, So Yeon
Kang, Cheol-In
Wi, Yu Mi
Chung, Doo Ryeon
Peck, Kyong Ran
Lee, Nam-Yong
Song, Jae-Hoon
Risk factors and molecular epidemiology of community-onset, multidrug resistance extended-spectrum β-lactamase-producing Escherichia coli infections
title Risk factors and molecular epidemiology of community-onset, multidrug resistance extended-spectrum β-lactamase-producing Escherichia coli infections
title_full Risk factors and molecular epidemiology of community-onset, multidrug resistance extended-spectrum β-lactamase-producing Escherichia coli infections
title_fullStr Risk factors and molecular epidemiology of community-onset, multidrug resistance extended-spectrum β-lactamase-producing Escherichia coli infections
title_full_unstemmed Risk factors and molecular epidemiology of community-onset, multidrug resistance extended-spectrum β-lactamase-producing Escherichia coli infections
title_short Risk factors and molecular epidemiology of community-onset, multidrug resistance extended-spectrum β-lactamase-producing Escherichia coli infections
title_sort risk factors and molecular epidemiology of community-onset, multidrug resistance extended-spectrum β-lactamase-producing escherichia coli infections
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5214718/
https://www.ncbi.nlm.nih.gov/pubmed/27093979
http://dx.doi.org/10.3904/kjim.2015.113
work_keys_str_mv AT parksoyeon riskfactorsandmolecularepidemiologyofcommunityonsetmultidrugresistanceextendedspectrumblactamaseproducingescherichiacoliinfections
AT kangcheolin riskfactorsandmolecularepidemiologyofcommunityonsetmultidrugresistanceextendedspectrumblactamaseproducingescherichiacoliinfections
AT wiyumi riskfactorsandmolecularepidemiologyofcommunityonsetmultidrugresistanceextendedspectrumblactamaseproducingescherichiacoliinfections
AT chungdooryeon riskfactorsandmolecularepidemiologyofcommunityonsetmultidrugresistanceextendedspectrumblactamaseproducingescherichiacoliinfections
AT peckkyongran riskfactorsandmolecularepidemiologyofcommunityonsetmultidrugresistanceextendedspectrumblactamaseproducingescherichiacoliinfections
AT leenamyong riskfactorsandmolecularepidemiologyofcommunityonsetmultidrugresistanceextendedspectrumblactamaseproducingescherichiacoliinfections
AT songjaehoon riskfactorsandmolecularepidemiologyofcommunityonsetmultidrugresistanceextendedspectrumblactamaseproducingescherichiacoliinfections